RC
SWTX

Rangeley Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Rangeley Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,400
Closed -$1.47M – 105
2025
Q1 		$1.47M Buy
+33,400
New +$1.54M 1.58% 22

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Rangeley Capital's SWTX Position: Q2 2025 in Review

Rangeley Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 33,400 shares — an estimated $1.47M sold.

Rangeley Capital first reported a position in SWTX in Q1 2025 and held it in 1 quarter. The position peaked at $1.47M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Rangeley Capital reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Rangeley Capital sold 33,400 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.47M.
  • Rangeley Capital first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 1 quarter.
  • Rangeley Capital's SpringWorks Therapeutics position peaked at $1.47M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.